www.benzinga.com ·
transcript organigram holdings q2 2026 earnings conference call
Topic context
This topic has been covered 256279 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article covers OrganiGram's Q2 2026 earnings, highlighting a slowdown in the Canadian recreational cannabis market and operational issues affecting vapes and pre-rolls. The company is launching new high-potency vape products and tightening quality controls. The commercial mechanism is weak: revenue decline and margin compression are company-specific, with no clear sector-wide supply/demand shock or regulatory change. The impact is single-company/supply-chain-specific, limited to OrganiGram and its product lines.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- OrganiGram reported a 9% year-over-year decline in net revenue in Q2 2026.
- Adjusted EBITDA fell to $0.9 million from $4.9 million year-over-year.
- Company expects net revenue to exceed $350 million for fiscal 2026.
- Sanity Group acquisition is expected to boost international sales.
- OrganiGram remains the number one licensed producer in Canada by market share.
